620
ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 5
MODERN APPROACHES TO THE DIAGNOSIS AND TREATMENT OF CHRONIC
PROSTATITIS: A CLINICAL AND LABORATORY ANALYSIS
Tursunov Yigitali Rajabovich
https://doi.org/10.5281/zenodo.15421008
Abstract. Chronic prostatitis, particularly chronic pelvic pain syndrome (CP/CPPS),
remains a significant diagnostic and therapeutic challenge in clinical urology. It is a
multifactorial syndrome with overlapping inflammatory, infectious, neurogenic, autoimmune,
and psychosocial components. The purpose of this study is to provide a comprehensive clinical
and laboratory evaluation of chronic prostatitis, focusing on modern diagnostic protocols and
treatment approaches. The study included clinical data from 80 patients with symptoms lasting
longer than three months, and combined both traditional and innovative diagnostics, such as
PCR-based pathogen identification, EPS analysis, and transrectal ultrasound. The results show
that a personalized, phenotype-based approach, especially using the UPOINT classification,
enhances therapeutic outcomes. Antibiotics remain effective in selected cases, but alpha-
blockers, physiotherapy, and anti-inflammatory agents also play vital roles. The study highlights
the importance of interdisciplinary collaboration and long-term patient monitoring.
Keywords: Chronic prostatitis, CP/CPPS, diagnosis, EPS, alpha-blockers, antibiotics,
UPOINT classification, pelvic pain, TRUS, microbiology
Introduction:
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is one of the
most prevalent and frustrating urological conditions encountered in men under 50. Although not
life-threatening, it significantly impairs quality of life and presents a broad spectrum of clinical
symptoms ranging from pelvic pain, urinary frequency, urgency, and painful ejaculation to
psychological distress, including anxiety and depression.
The pathophysiology of CP/CPPS is complex and incompletely understood. The
condition is classified as type III prostatitis by the NIH, and further subclassified into IIIA
(inflammatory) and IIIB (non-inflammatory) types. While type II chronic bacterial prostatitis has
a clear infectious etiology, most CP/CPPS cases lack identifiable pathogens. Therefore,
treatment is often empirical, multifactorial, and prolonged.
Modern medicine has introduced a variety of tools and methodologies to improve
diagnosis and patient stratification. Among them are advanced imaging, molecular diagnostics
(e.g., PCR), and validated symptom questionnaires like NIH-CPSI. Similarly, treatment options
have expanded from empiric antibiotic therapy to include alpha-blockers, anti-inflammatory
agents, phytotherapy, behavioral therapy, and pelvic floor physiotherapy.
This study aims to assess current approaches to the diagnosis and management of chronic
prostatitis using clinical and laboratory data, and to explore the effectiveness of multimodal
treatment strategies.
Materials and Methods
This was a prospective observational study conducted at a tertiary urology clinic over a
period of 18 months (January 2023 – June 2024). A total of 80 male patients aged between 25
and 55 years with symptoms of chronic pelvic pain syndrome lasting for more than 3 months
were included.
Inclusion Criteria:
a.
Male patients aged 25–55 years
b.
Symptoms of pelvic or perineal pain >3 months
621
ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 5
c.
No evidence of urinary tract infection or cancer
Exclusion Criteria:
a.
History of recent urological surgery
b.
Active sexually transmitted infection
c.
Neurological disorders affecting bladder function
Clinical Assessment Tools:
a.
NIH Chronic Prostatitis Symptom Index (NIH-CPSI)
b.
International Prostate Symptom Score (IPSS)
c.
Physical examination including digital rectal exam (DRE)
Laboratory Investigations:
a.
Urinalysis and urine culture
b.
Four-glass Meares–Stamey test and simplified two-glass test (VB1 and VB3)
c.
Expressed Prostatic Secretion (EPS) analysis (leukocyte count and culture)
d.
PCR testing for Chlamydia, Ureaplasma, Mycoplasma, and other uropathogens
e.
Semen analysis and culture (selective)
Imaging and Functional Tests:
a.
Transrectal Ultrasonography (TRUS) for prostate volume and echogenicity
b.
Uroflowmetry and post-void residual urine estimation
Treatment Groups
:
Patients were stratified based on UPOINT classification and divided into four therapeutic
groups:
1. Group A: Antibiotic + alpha-blocker
2. Group B: Alpha-blocker + phytotherapy
3. Group C: Anti-inflammatory + physiotherapy
4. Group D: Multimodal treatment (based on UPOINT)
Follow-ups were conducted at 4, 8, and 12 weeks post-treatment, with re-evaluation of
symptoms using NIH-CPSI and clinical examination.
Results
a.
Demographics:
b.
Mean age: 39.5 ± 8.7 years
c.
Duration of symptoms: Mean 7.2 months
d.
Type IIIA: 37 patients (46.25%)
e.
Type IIIB: 43 patients (53.75%)
Common Symptoms Reported
:
a.
Perineal/pelvic pain: 100%
b.
Dysuria: 56%
c.
Painful ejaculation: 42%
d.
Erectile dysfunction: 39%
e.
Lower back pain: 34%
Laboratory Findings
:
a.
Positive leukocyte count in EPS: 38 cases (mostly type IIIA)
b.
Positive PCR for Ureaplasma urealyticum: 22 patients
c.
Positive culture: 18 cases (low-grade bacterial flora)
d.
TRUS abnormalities (prostate calcifications, hypoechoic zones): 47 patients
622
ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 5
Treatment Efficacy
:
a.
Group D (multimodal): 74% showed >50% improvement in NIH-CPSI score
b.
Group A: 61% improvement
c.
Group B: 48% improvement
d.
Group C: 53% improvement
Side Effects
:
Mild orthostatic hypotension in 6 patients on alpha-blockers
Gastrointestinal complaints in 4 patients on NSAIDs
Discussion
The study confirms that chronic prostatitis is a heterogeneous syndrome that requires a
comprehensive diagnostic approach and individualized therapy. The traditional view of
prostatitis as a purely infectious disease is outdated. Our data supports the use of the UPOINT
system, which allows for categorization based on urinary, psychosocial, organ-specific,
infection-related, neurologic/systemic, and tenderness domains.
Alpha-blockers, especially tamsulosin, remain effective for urinary symptoms.
Antibiotics were beneficial only in PCR-positive or EPS-positive patients, reinforcing the
importance of microbiological confirmation before prescribing antimicrobials. Phytotherapeutic
agents like quercetin and Serenoa repens showed moderate benefits in inflammatory types, with
good tolerability.
Pelvic floor physiotherapy and cognitive-behavioral therapy (CBT) were essential for
patients with pelvic floor dysfunction and anxiety-related symptoms. This highlights the
psychosomatic interplay in CP/CPPS and the importance of interdisciplinary care involving
urologists, psychologists, and physiotherapists.
The biggest improvements were seen in the group receiving multimodal therapy tailored
to their UPOINT profile, emphasizing that no single treatment fits all. Long-term management
and patient education remain crucial in achieving sustained remission.
Conclusion
Chronic prostatitis/CPPS is a multifactorial syndrome that requires a personalized and
structured approach to diagnosis and treatment. Laboratory evaluations, particularly PCR
diagnostics and EPS analysis, play a key role in differentiating inflammatory and infectious
components. Treatment should be based on symptom phenotype, and the UPOINT system is an
effective tool for guiding therapy.
A combination of alpha-blockers, anti-inflammatory agents, physiotherapy, and patient
education yields the best outcomes. Future directions should focus on better understanding the
neuroimmune mechanisms of CP/CPPS and integrating emerging therapies such as microbiome
modulation and neuromodulation.
REFERENCE
S
1.
Долиев, М. Н., Тулакова, Г. Э., Кадырова, А. М., Юсупов, З. А., & Жалалова, Д. З.
(2016). Эффективность комбинированного лечения пациентов с центральной
серозной
хориоретинопатией.
Вестник
Башкирского
государственного
медицинского университета, (2), 64-66.
2.
Andryev S. et al. Experience with the use of memantine in the treatment of cognitive
disorders //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 282-288.
623
ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 5
3.
Antsiborov S. et al. Association of dopaminergic receptors of peripheral blood
lymphocytes with a risk of developing antipsychotic extrapyramidal diseases //Science
and innovation. – 2023. – Т. 2. – №. D11. – С. 29-35.
4.
Asanova R. et al. Features of the treatment of patients with mental disorders and
cardiovascular pathology //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 545-
550.
5.
Begbudiyev M. et al. Integration of psychiatric care into primary care //Science and
innovation. – 2023. – Т. 2. – №. D12. – С. 551-557.
6.
Bo’Riyev B. et al. Features of clinical and psychopathological examination of young
children //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 558-563.
7.
Borisova Y. et al. Concomitant mental disorders and social functioning of adults with
high-functioning autism/asperger syndrome //Science and innovation. – 2023. – Т. 2. –
№. D11. – С. 36-41.
8.
Ivanovich U. A. et al. Efficacy and tolerance of pharmacotherapy with antidepressants in
non-psychotic depressions in combination with chronic brain ischemia //Science and
Innovation. – 2023. – Т. 2. – №. 12. – С. 409-414.
9.
Nikolaevich R. A. et al. Comparative effectiveness of treatment of somatoform diseases
in psychotherapeutic practice //Science and Innovation. – 2023. – Т. 2. – №. 12. – С. 898-
903.
10.
Novikov A. et al. Alcohol dependence and manifestation of autoagressive behavior in
patients of different types //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 413-
419.
11.
Pachulia Y. et al. Assessment of the effect of psychopathic disorders on the dynamics of
withdrawal syndrome in synthetic cannabinoid addiction //Science and innovation. –
2023. – Т. 2. – №. D12. – С. 240-244.
12.
Pachulia Y. et al. Neurobiological indicators of clinical status and prognosis of
therapeutic response in patients with paroxysmal schizophrenia //Science and innovation.
– 2023. – Т. 2. – №. D12. – С. 385-391.
13.
Pogosov A. et al. Multidisciplinary approach to the rehabilitation of patients with
somatized personality development //Science and innovation. – 2023. – Т. 2. – №. D12. –
С. 245-251.
14.
Pogosov A. et al. Rational choice of pharmacotherapy for senile dementia //Science and
innovation. – 2023. – Т. 2. – №. D12. – С. 230-235.
15.
Pogosov S. et al. Gnostic disorders and their compensation in neuropsychological
syndrome of vascular cognitive disorders in old age //Science and innovation. – 2023. –
Т. 2. – №. D12. – С. 258-264.
16.
Pogosov S. et al. Prevention of adolescent drug abuse and prevention of yatrogenia
during prophylaxis //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 392-397.
17.
Pogosov S. et al. Psychogenetic properties of drug patients as risk factors for the
formation of addiction //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 186-191.
18.
Sedenkov V. et al. Clinical and socio-demographic characteristics of elderly patients with
suicide attempts //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 273-277.
19.
Sedenkov V. et al. Modern methods of diagnosing depressive disorders in neurotic and
affective disorders //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 361-366.
624
ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 5
20.
Zukhridinovna, Z. D. (2022). Modern aspects of neuroprotective treatment in
hypertensive retinopathy.
21.
Jalalova, D., Raxmonov, X., & Shernazarov,
F. (2022). THE ROLE OF C-REACTIVE
PROTEIN IN THE PATHOGENESIS OF VISUAL VASCULAR DISEASES IN PATIENTS
WITH ARTERIAL HYPERTENSION.
Science and Innovation, 1(8), 114-121.
22.
Jalalova, D., Raxmonov, X., & Shernazarov, F. (2022). SIGNIFICANCE OF
ENDOTHELIAL DYSFUNCTION IN THE DEVELOPMENT OF RETINOPATHY IN
PATIENTS WITH AH AND WAYS OF ITS CORRECTION. Science and Innovation,
1(8), 101-113.
23.
Jalalova, D., Axmedov, A., Kuryazov, A., & Shernazarov, F. (2022). COMBINED
DENTAL AND EYE PATHOLOGY. Science and innovation, 1(8), 91-100.
24.
Саттарова, Х. С., Жалалова, Д. З., & Бектурдиев, Ш. С. (2011). Причины слепоты и
слабовидения при сахарном диабете. Академический журнал Западной Сибири, (6),
27-28.
25.
Arunachalam, S. (2008). The science race continues in Asia. Current Science
(00113891), 94(7).
26.
Zukhriddinovna, Z. D. (2022). Development of Classification Criteria for Neuroretinal
Ischemia in Arterial Hypertension. Central Asian Journal of Medical and Natural
Science, 3(3), 59-65.
27.
Жалалова, Д. З., & Исмоилов, Ж. Ж. (2024). ТЕОРЕТИЧЕСКОЕ ОБОСНОВАНИЕ
ИССЛЕДОВАНИЯ ЭНДОТЕЛИНА-1 И Д-ДИМЕРОВ В КРОВИ И СЛЕЗНОЙ
ЖИДКОСТИ ПАЦИЕНТОВ С ГИПЕРТОНИЧЕСКОЙ АНГИОРЕТИНОПАТИЕЙ.
AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI, 3(3), 294-299.
28.
Киселева, Т. Н., Ежов, М. В., Аджемян, Н. А., Танковский, В. Э., & Ильина, Н. В.
(2016). Особенности регионарного глазного кровотока при артериальной
гипертензии I-II степени и субклиническом атеросклерозе. Российский
офтальмологический журнал, 9(3), 26-33.
29.
Жалалова, Д. З., Кадирова, А. М., & Хамракулов, С. Б. (2021). Исходы
герпетических кератоувеитов на фоне лечения препаратом «офтальмоферон» в
зависимости от иммунного статуса пациентов. междисциплинарный подход по
заболеваниям органов головы и шеи, 103.
30.
Дроздова, Е. А., & Хохлова, Д. Ю. (2015). Морфометрическая характеристика
макулярной зоны у пациентов с окклюзией вен сетчаткипо данным оптической
когерентной томографии. Медицинский вестник Башкортостана, 10(2 (56)), 64-67.
31.
Jalalova, D., Axmedov, A., Kuryazov, A., & Shernazarov, F. (2022). СОЧЕТАННАЯ
СТОМАТОЛОГИЧЕСКАЯ И ГЛАЗНАЯ ПАТОЛОГИЯ. Science and innovation,
1(D8), 91-100.
32.
Zhang, S., & Melander, S. (2014). Varicose veins: Diagnosis, management, and
treatment. The Journal for Nurse Practitioners, 10(6), 417-424.
33.
Жалалова, Д. З., & Бабаев, С. А. (2024). РЕЗУЛЬТАТЫ ОЦЕНКИ УРОВНЯ
ЭНДОТЕЛИНА-1 И Д-ДИМЕРОВ В СЛЕЗНОЙ ЖИДКОСТИ У ПАЦИЕНТОВ С
АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ. AMALIY VA TIBBIYOT FANLARI ILMIY
JURNALI, 3(3), 300-307.
625
ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 5
34.
Zukhriddinovna, Z. D. (2022). Development of Classification Criteria for Neuroretinal
Ischemia in Arterial Hypertension. Central Asian Journal of Medical and Natural
Science, 3(3), 59-65.
